Assessment of dependence and motivation to stop smokingBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7435.338 (Published 05 February 2004) Cite this as: BMJ 2004;328:338
- Robert West, professor of health psychology
Whether a smoker succeeds in stopping smoking depends on the balance between that individual's motivation to stop smoking and his or her degree of dependence on cigarettes. Clinicians must be able to assess both of these characteristics. Motivation is important because “treatments” to assist with smoking cessation will not work in smokers who are not highly motivated. Dependence is especially important in smokers who do want to stop smoking, as it influences the choice of intervention. It is also important to bear in mind that:
Motivation to stop and dependence are often related to each other: heavy smokers may show low motivation because they lack confidence in their ability to quit; lighter smokers may show low motivation because they believe they can stop in the future if they wish
Motivation to stop can vary considerably with time and be strongly influenced by the immediate environment
What smokers say about their wish to stop, especially in a clinical interview, may not accurately reflect their genuine feelings.
Measuring dependence in smokers
The simplest approach to measuring dependence on cigarettes is a basic qualitative approach that uses questions to find out whether the smoker has difficulty in refraining from smoking in circumstances when he or she would normally smoke or whether the smoker has made a serious attempt to stop in the past but failed.
The most commonly used quantitative measure of dependence is the Fagerstrom test for nicotine dependence, which has proved successful in predicting the outcome of attempts to stop. The higher the score on this questionnaire, the higher the level of dependence: smokers in the general population score an average of about 4 on this scale. Of all the items in the questionnaire, cigarettes per day and time to first cigarette of the day seem to be the most important indicators of dependence.
The concentration of nicotine or its metabolite, cotinine, in blood, urine, or saliva is often used in research as an objective index of dependence because it provides an accurate measure of the quantity of nicotine consumed, which is itself a marker of dependence. Carbon monoxide concentration of expired air is a measure of smoke intake over preceding hours; it is not as accurate an intake measure as nicotine based measures, but it is much less expensive and gives immediate feedback to the smoker.
How should dependence influence choice of treatment?
The main value of measuring dependence in tailoring cessation interventions to individual smokers is in the choice of pharmacotherapy. The manufacturers of smoking cessation drug products (principally nicotine replacement therapy and bupropion—see later chapters in this series) recommend that only smokers of 10 or more cigarettes a day should use their products. However, the UK National Institute for Clinical Excellence has recently recognised this cut off to be arbitrary and has not specified any particular lower limit for daily cigarette consumption.
This article reviews some simple methods to assess dependence and motivation in smokers
Measuring motivation to stop smoking
Survey evidence in the United Kingdom shows that about two thirds of smokers declare that they want to stop smoking and that in any year almost a third make an attempt to stop. Young smokers are widely believed to be less motivated to stop than older smokers, but in fact the reverse is true: older smokers are typically less motivated.
However, only a minority of smokers attempting to stop currently use smoking cessation medications or attend a specialist cessation service. This may reflect a lack of confidence among smokers that these treatments will help.
Motivation to stop can be assessed qualitatively by means of simple direct questions about their interest and intentions to quit. This simple approach is probably sufficient for most clinical practice, although slightly more complex, semiquantitative measures (asking the smoker to rate degree of desire to stop on a scale from “not at all” to “very much”) can also be used.
Stages of change
One model of the process of behaviour change has become popular: the “transtheoretical model.” In this model, smokers are assigned to one of five stages of motivation: precontemplation (not wishing to stop), contemplation (thinking about stopping but not in the near future), preparation (planning to stop in the near future), action (trying to stop), and maintenance (have stopped for some time). Smokers may cycle through the contemplation to action stages many times before stopping for good. This model has been widely adopted, though no evidence exists that the rather elaborate questionnaires for assigning smokers to particular stages predict smoking cessation better than the simple direct questions outlined above.
Some clinicians use a smoker's degree of motivation to stop as a prognostic indicator of likely success once the quit attempt has been decided. In fact, degree of motivation seems to play a fairly small role in success; once a quit attempt is made, markers of dependence are far stronger determinants of success. The ultimate practical objective of assessing motivation is therefore to identify smokers who are ready to make a quit attempt. After that, it is the success of the intervention in overcoming dependence that matters.
Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend 1994;34: 211-6.
National Institute for Clinical Excellence. Technology appraisal guidance No 38. Nicotine replacement therapy (NRT) and bupropion for smoking cessation. London: NICE, 2002.
Sutton S. Back to the drawing board? A review of applications of the transtheoretical model to substance use. Addiction 2001;96: 175-86.
The ABC of smoking cessation is edited by John Britton, professor of epidemiology at the University of Nottingham in the division of epidemiology and public health at City Hospital, Nottingham. The series will be published as a book in the late spring.
Competing interests RW has done paid research and consultancy for, and received travel funds and hospitality from, manufacturers of smoking cessation products, including nicotine replacement therapies and Zyban. See first article in this series (24 January 2004) for the series editor's competing interests.